AB122 is a monoclonal antibody that is effective in generating an anti-tumor response by interfering the ability of T-cells. The antibody blocks a protein called PD-1. Tumor-infiltrating T-cells recognize tumor antigens and express this immune checkpoint.
PD-L1 and PD-L2 proteins are brought into existence which interacts with the PD-1 cancer cells. These proteins also interact with the immune cells in the tumor Micro-Environment which interferes with the ability of T-cells to produce an effective response against a tumor. AB122 performs its role in anti-tumor activity by blocking the interaction between PD-L1 and its ligands. This agent has received regulatory approval like other agents in this class.
The major role of AB122 is in treating solid tumors. Whenever a person is having a solid tumor, it means that his tumor is without any liquid or cyst. Solid tumor might occur in bones, muscles or organs. Solid tumor includes cancer of the brain, colon, breast, ovary, and other tissues. They might be benign or malignant. Sarcomas, lymphomas, and carcinomas are examples of solid tumors.
Researchers from Central Texas Veterans Healthcare System in Temple and University of Texas MD Anderson Cancer Center in Houston pointed out that too little vitamin D increases the chances of death in older cancer patients who are victims of a solid tumor.
According to the Arcus Biosciences Phase-1 trial, stability and tumor reduction were achieved in patients with solid tumors after being treated through antibody AB122. Patients suffering from ovarian cancer and other advanced tumors came up with stability after antibody treatment. “So this approved this potential antibody treatment as findings showed that results were similar to other approved therapies.”